In this article, we will look at the 10 Most Promising Cancer Stocks According to Hedge Funds.

According to the World Health Organization (WHO), cancer remains one of the leading causes of death globally, responsible for nearly 10 million deaths in 2020, or about one in six deaths worldwide. Moreover, the World Cancer Research Fund reports that approximately 18.1 million cancer cases were diagnosed that year, with the age-standardized rate, when considering all cancers except non-melanoma skin cancer and combining data for both men and women, came in at 190 cases per 100,000 individuals. This rate was notably higher in men, with 206.9 cases per 100,000, compared to 178.1 per 100,000 in women.

Cancer drugs are usually aimed at slowing cell replication or selectively killing cancer cells at a faster rate than healthy cells. While this approach has been effective for certain cancers, innovative strategies are now emerging. These include modifying immune cells, harnessing mRNA, and improving early detection through simple blood tests. Advancing our understanding, prevention, screening, and treatment of cancer is essential for reducing its global impact, yet it comes with escalating costs—global oncology spending is expected to exceed $250 billion this year.

In response, biotech and pharmaceutical companies are in a competitive race to develop cutting-edge technologies and therapies for major cancers like lung, breast, and prostate. In that vein, targeting tumors directly with radiation is poised to be a significant breakthrough in cancer treatment. Leading pharmaceutical companies have invested around $10 billion in acquisitions and partnerships with radiopharmaceutical developers, often acquiring smaller, innovative companies to access this promising technology. Though still in its early stages, radiopharmaceuticals hold the potential to treat a wide range of cancers. The first such drugs were approved in the early 2000s, but only recently have major pharmaceutical companies shown substantial interest.

Reflecting on this trend, Guggenheim Securities analyst Michael Schmidt remarked, “Any large company that has a business presence in oncology or for whom oncology is an important therapeutic category will probably need exposure in this area one way or another.” Schmidt projects that if radiopharmaceuticals remain focused on treating specific cancers, like prostate and neuroendocrine tumors, the sector could generate at least $5 billion in revenue. However, if proven effective in treating a broader range of cancers, this figure could rise to tens of billions.

Since there is no universal cure for cancer, developing a drug capable of treating multiple cancer types is incredibly lucrative. This dynamic fuels continuous breakthroughs in the oncology market, significantly boosting its growth potential. On that front, the oncology pipeline is expanding rapidly, with over 2,000 products currently in development. Notably, 71% of these are being developed by mid-sized, high-growth biopharmaceutical firms, which have significantly increased their investment in cancer treatment innovations from 51% in 2017.

Over the past two decades, 237 new active substances for cancer have been introduced globally, with approximately 115 launched in the last five years alone. Moreover, the global oncology market was valued at approximately $201.75 billion in 2023 and is projected to exceed $518.25 billion by 2032, growing at a compound annual rate (CAGR) of 11.3% from 2024 to 2032, according to Fortune Business Insights. This expansion is fueled by rising prevalence of the disease, the introduction of new therapies, regulatory approvals, and advancing research in the field.

Our Methodology

To compile our list of the 10 most promising cancer stocks to buy according to hedge funds, we started by evaluating companies in the cancer therapy sector using ETF holdings and media analysis. We then narrowed down the list to notable stocks with an average analyst upside of at least 30% and favorable analyst ratings. From this selection, we identified the top cancer companies with the most hedge fund investors, based on Insider Monkey’s database of 900 hedge funds, as of Q3 2024.

At Insider Monkey, we are obsessed with the stocks that hedge funds pile into. The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).

10. Immunitybio Inc. (NASDAQ:IBRX)

Average Analyst Upside: 162.92%

Number of Hedge Fund Holders: 8

ImmunityBio, Inc. (NASDAQ:IBRX) is a biotechnology firm dedicated to pioneering new cancer therapies through cellular immunotherapy, an approach that harnesses the body’s immune system to target cancer cells.

In October, EF Hutton initiated coverage of ImmunityBio, Inc. (NASDAQ:IBRX) with a Buy rating and a $30 price target, an upside of over 600%, reflecting confidence in the company’s potential. ImmunityBio’s lead product, Anktiva, is central to its innovative cancer treatment strategy. Anktiva is an interleukin-15 (IL-15) superagonist designed to activate natural killer (NK) cells and generate CD8+ memory T cells, which are essential for identifying and eradicating tumor cells, particularly those that evade immune detection by suppressing MHC molecules. This mechanism enables Anktiva to convert “cold” tumors, which are typically resistant to immune attacks, into “hot” tumors, making them more vulnerable to the immune system.

Additionally, ImmunityBio, Inc. (NASDAQ:IBRX) recently secured an exclusive global partnership with the Serum Institute of India to produce Bacillus Calmette-Guerin (BCG) for use with Anktiva. This combination therapy, targeting non-muscle invasive bladder cancer, recently gained U.S. FDA approval.

9. Tango Therapeutics Inc. (NASDAQ:TNGX)

Average Analyst Upside: 372.54%

Number of Hedge Fund Holders: 17

Tango Therapeutics Inc. (NASDAQ:TNGX) is a clinical-stage biotech company focused on developing precision cancer therapies using synthetic lethality to discover new drug targets.

In its Q3 report, Tango Therapeutics Inc. (NASDAQ:TNGX) announced a solid cash position of $293 million, $11.6 million in collaboration revenue, and a net loss of $29.2 million. With this strong cash reserve, the company plans to fund operations through Q3 2026, prioritizing clinical trial programs aimed at transforming cancer treatment.

The company has made significant progress in its pipeline, advancing its candidate TNG462 into full development after promising early trial results, particularly for non-small cell lung cancer (NSCLC) and pancreatic cancer. Meanwhile, it decided to halt enrollment for TNG908 to reallocate resources to TNG462 and TNG456, which targets glioblastoma, NSCLC, and other solid tumors.

In late October, Leerink Partners reaffirmed its Outperform rating on Tango Therapeutics Inc. (NASDAQ:TNGX) with a price target of $19, ahead of the company’s year-end clinical update for its PRMT5 inhibitor programs, TNG462 and TNG908. The data release was anticipated to be a key catalyst for the stock, with Tango Therapeutics Inc. (NASDAQ:TNGX) expected to present data on approximately 30-35 patients treated with TNG462, including about 20 at the expansion doses, and data on 60-65 patients for TNG908, featuring at least 10 at the 600mg BID dose and 15-20 glioblastoma patients.